Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDNO in COVID-19 Patients With Acute Pulmonary Hypertension
NCT04885491Phase 2Withdrawn
- Sponsor
- Attgeno AB
- Start
- May 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PDNO in pulmonary hypertension (PH), cor pulmonale, sponsored by Attgeno AB. Planned start May 2021; status: withdrawn.
02
Drugs
PDNO
03
Conditions
pulmonary hypertension (PH)cor pulmonale
Beyond the preview
Go deeper on NCT04885491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04885491.